Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Antidepressant plus hearing-aid mood and cognition study

Also known as: Duloxetine or escitalopram, Phonak Audeo B-R 90 hearing aid study, Treating hearing loss to improve mood and cognition

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Procedure/Rehab

Modality

Hearing Aid/Medication Combination Study

Stage

Phase 4

Status

Completed

Target Gene

—

Route / Mode

Oral antidepressant plus hearing-aid fitting

Confidence

88%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

older-adult, age-related, hearing-aid

Trial IDs

Mechanism

Randomized Phase 4 study of antidepressant treatment plus active full-amplification versus sham low-amplification Phonak hearing aids in older adults with hearing loss and depression.

Indications

Hearing Loss Age-Related Hearing Loss

Notes

Registry-verified academic/NIA study using duloxetine or escitalopram with active or sham Phonak hearing aids. Phonak devices were used, but the registry does not list industry sponsorship; this is not a standalone antidepressant hearing-loss product.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...

IDs: NCT03321006

Open

Key Events

2018-05-30

Hearing loss mood/cognition intervention study started

2021-06-01

Study completed

Clinical Trials (1)